No insurance is needed, we offer transparent out-of-pocket prices
In the STEP 1 trial, dual-energy X-ray absorptiometry (DXA) substudies showed that semaglutide treatment resulted in a greater proportional decrease in fat mass compared to lean body mass over 68 weeks, though absolute lean mass reductions were observed alongside the predominant fat loss
CagriSema is a fixed-dose combination therapy comprising two molecules administered together in a single once-weekly subcutaneous injection: semaglutide 2.4 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist already approved for weight management as Wegovy, and cagrilintide 2.4 mg, a long-acting analogue of amylin, a hormone involved in appetite regulation and satiety signalling
262 The accumulation of amyloid fibrils in the cardiac extracellular matrix induces myocardial stiffness and conduction disturbances, leading to clinical manifestations such as HF and arrhythmias
You will hear a click when the injection starts and a second click when it is finishing